Pre-eclampsia and hypertensive disorders of pregnancy are frequently associated with foeto-placental growth restriction, and that may be triggered by angiogenic imbalance and endothelial dysfunction. Impaired nitric oxide (NO) bioavailability seems to be involved in these pathophysiological changes observed in hypertensive pregnancy. Pravastatin has shown efficacy and to be safe during hypertension in pregnancy. However, NO involvement in pravastatin effects during maternal hypertension and foeto-placental development is unclear. Therefore, we aimed to examine pravastatin effects on placental NO formation, endothelium-dependent vasodilation, systolic blood pressure and foeto-placental development in hypertensive pregnant rats. Biochemical determinants of angiogenesis and oxidative stress were also assessed. Pregnant rats were distributed into four groups: normal pregnancy (Norm-Preg), pregnancy+pravastatin (Preg-Prava), hypertensive pregnancy (HTN-Preg) and hypertensive pregnancy+pravastatin (HTN-Preg+Prava). Our results showed that pravastatin treatment blunts hypertension and foeto-placental growth restriction. Also, increases in placental NO levels were found in the HTNPreg+Prava group. Pravastatin prevents impaired endothelium-dependent acetylcholine-induced vasodilation, exacerbated contractile response to phenylephrine and increases in oxidative stress in the HTN-Preg+Prava group. Increased soluble fms-like tyrosine kinase-1-to-placental growth factor (sFlt-1/PlGF) ratio is reversed by pravastatin treatment in the HTN-Preg+Prava group. We conclude that NO formation and endothelium-dependent vasodilation underlie pleiotropic effects associated with pravastatin treatment against hypertension in pregnancy, intrauterine growth restriction, vascular dysfunction and angiogenic imbalance.
| INTRODUCTION
Statins are clinically prescribed for cholesterol biosynthesis inhibition and for preventing the onset and progression of atherosclerotic cardiovascular disease. 1 Although statin usage to this end is supported by decades of preclinical investigations and clinical trials, 2, 3 additional and beneficial effects have been revealed. 4 In this regard, pleiotropic effects of statins have been associated with nitric oxide (NO) signalling, 5, 6 and pravastatin markedly increased endotheliumdependent vasodilation in spontaneously hypertensive male rats. 7 Moreover, recent studies have demonstrated that pravastatin presents favourable safety and pharmacokinetic profiles to its use during pregnancy. 8, 9 Pravastatin has shown protective effects during foetal development in gestational hypertension in animals. 10, 11 In addition, in humans, pravastatin effects involved augmented levels of vasodilator NO 10 that prevented the onset of pre-eclampsia 9 and attenuated the intrauterine growth restriction. 10, 12 However, these cholesterol-independent mechanisms due to pravastatin have not yet been fully clarified in hypertensive disorders of pregnancy correlated with foetal growth restriction. A marked foetal growth and uteroplacental vascularization arise during pregnancy, 13 and previous evidence in vitro suggests that NO produced into human foetoplacental circulation contributes to the maintenance of adequate blood supply to the growing foetus. 14 Also, NO seems to be involved in modulation of placental growth factor (PlGF) and soluble fms-like tyrosine kinase-1 (sFlt-1), the key molecules in angiogenesis and vasculogenesis. 15 These findings are particularly interesting, since complications of pre-eclampsia involve endothelial and vascular dysfunctions that may be caused by angiogenic imbalance, pro-oxidant state and reduced NO bioavailability. [16] [17] [18] Therefore, in the present study, we used an animal model of hypertensive pregnancy induced by deoxycorticosterone acetate (DOCA) and sodium chloride (DOCAsalt), which results from the imposition of excessive volume expansion 19 and which in previous studies has
shown that DOCA-salt-treated pregnant rats developed hypertension, foetal growth restriction, endothelial dysfunctions and other pre-eclamptic features. 19, 20 Accordingly, we aimed to investigate whether NO signalling underlies pravastatin pleiotropic effects in foeto-placental interface and in endothelium-dependent vasodilation. In order to examine these mechanisms in hypertension in pregnancy, we measured maternal blood pressure, foetal and placental weights, placental NO formation and vascular and endothelial functions, and we also evaluated biochemical determinants of angiogenesis and oxidative stress after pravastatin treatment.
| MATERIALS AND METHODS

| Animals and experimental protocols
Wistar rats (200-250 g) were housed in cages at 22 ± 2°C on a 12-hour light/dark cycle and given free access to water and rat chow. Each female rat was separately mated overnight. Day 1 of pregnancy was defined when spermatozoa were found in a vaginal smear. Hypertensive pregnancy was induced by the DOCA-salt model. Briefly, pregnant rats were injected with 12.5 mg of DOCA (#D7000; Sigma, St. Louis, MO, USA) intraperitoneally (i.p.) in a depot form on gestational day 1, followed by i.p. injections of DOCA (6.5 mg) on gestational days 7 and 14. Moreover, drinking water was replaced by 0.9% saline solution throughout gestation, as previously described. 19, 20 Pregnant rats were randomized and assigned to four groups: pregnant rats receiving daily 0.9% saline solution (0.3-0.45 mL) injections (i.p.) and potable water (0.3-0.45 mL) via gavage (Norm-Preg, n = 10); pregnant rats submitted to the DOCA-salt model and treated with potable water via gavage (HTN-Preg, n = 10); pregnant rats receiving 0.9% saline solution injections (i.p.) and pravastatin solubilized in potable water (10 mg/kg per daily) via gavage (0.3-0.45 mL, Preg-Prava, n = 10); and pregnant rats submitted to the DOCA-salt model and treated with pravastatin (10 mg/kg per daily) via gavage (HTN-Preg+Prava, n = 10). Rats received pravastatin from gestational days 10 to 19. Pravastatin was given to the animals 3 hour before systolic blood pressure measurements. Pravastatin dosage was chosen based on its elimination half-life and likewise on the lowest dose used in women with pre-eclampsia. 8, 9 Animals were killed on gestational day 19 under overdose of isoflurane followed by exsanguination. Soon after killing, dams were placed in a supine position and a caesarean section was performed. Then, foetal and placental weights and litter size (total number of pups) were recorded. Blood samples were collected in lyophilized heparin-containing tubes (Vacutainer; Becton Dickinson, Oxford, UK) and immediately centrifuged for plasma separation. Plasma was stored at −80°C until use for biochemical analysis.
All procedures for animal experimentation were approved by the Institutional Ethics Committee (protocol no. 960/2017), which complied with international guidelines of the European Community for the use of experimental animals. The study was conducted in accordance with the BCPT policy for experimental and clinical studies. 21 
| Blood pressure measurements
Systolic blood pressure (mmHg) was measured using tailcuff plethysmography (Insight, Ribeirao Preto, Sao Paulo, Brazil, catalogue #EFF-306). Briefly, conscious rats were first acclimated in a quiet room, conditioned and restrained in a warm-box (Insight, Ribeirao Preto, Sao Paulo, Brazil, catalogue #EFF-307) at 40°C for 5-10 min. Systolic blood pressure was determined as the average of the cuff inflation-deflation (3-6 cycles) by a trained operator. 22 We used Griess reagents followed by reduction of nitrous species with vanadium chloride III to examine NOx concentrations. 23 Briefly, placental tissue was homogenized in cold Krebs solution and the homogenates were centrifuged at 15 000×g at 4°C for 15 minutes. Supernatant was removed and incubated with 100 μL of saturated solution of vanadium chloride III for 3 hour at 37°C with agitation for nitrate reduction. After incubation, 50 μL of 1% sulphanilamide solution in 5% phosphoric acid was added and plate-incubated for 10 minutes, protected from light. Then, 50 μL of 0.1% N-(1-naphthyl)-ethylenediamine dihydrochloride solution was added followed by 10-minutes incubation in the dark. Absorbance at 535 nm was read in spectrophotometer (Synergy 4; BIOTEK, Winooski, VT, USA), and NOx concentration was calculated using a standard curve of sodium nitrite (1.56-100 μmol/L). The NOx levels in placental tissue were expressed as μmol/100 mg tissue.
| Determination of placental lipid peroxidation
Lipid peroxidation was determined through measurements of thiobarbituric acid (TBA)-reactive substances (TBARS). Briefly, TBA reacts with malondialdehyde (MDA), which is the end product of lipid peroxidation and produces a colorimetric reaction that is measured by spectrophotometer at a wavelength of 532 nm. 24 In test tubes, a reaction mixture containing 100 μL of distilled water, 50 μL of 8.1% sodium dodecyl sulphate (SDS), 100 μL of samples, 375 μL of acetic acid 20% and 375 μL of TBA 0.8% was incubated in a water bath at 95°C for 1 hour and subsequently centrifuged at 15 000×g for 10 minutes. Standard curve was prepared in a similar manner, replacing samples with 25 μL of known concentrations of MDA. Placental TBARS were calculated against a standard curve of MDA (20-320 nmol). The results were expressed as MDA levels/100 mg tissue.
| Determination of plasma sFlt-1 and PlGF levels
Commercial enzyme immunoassay (ELISA) kits for sFlt-1 (#ELM-VEGFR1; RayBiotech Inc., Norcross, GA, USA)
and PlGF (#E-EL-R0742; Elabscience Inc., Houston, TX, USA) were used. Assays were performed according to the manufacturer's instructions. Plasma levels were expressed in pg/mL.
| Vascular reactivity
Thoracic aortas were dissected and rings were obtained (3-4 mm). The aortic rings were placed into a 10-mL organ chamber containing Krebs-Henseleit solution (NaCl 130; KCl 4.7; CaCl 2 1.6; KH 2 PO 4 1.2; MgSO 4 1.2; NaHCO 3 15; glucose 11.1, in mmol/L) kept at pH 7.4 and 37°C and bubbled continuously with a mixture of 95% O 2 and 5% CO 2 . Rings were suspended between two wire hooks. One hook was fixed to a stationary support, and the other hook was connected to an isometric force transducer. Changes in aorta tension were recorded using FORT10 isometric force transducers connected to Transbridge 4M Transducer Amplifier (WPI, Sarasota, FL, USA) connected to a PCbased MP100 System and analysed offline using AcqKnowledge version 3.5.7 software (Biopac Systems Inc., Goleta, CA, USA). Thoracic aorta rings were stretched under 1.5 g basal tension and were allowed to equilibrate for 45 minutes. After tissue equilibration, a control contraction to 96 mmol/L of KCl was elicited. Once KCl maximum contraction was reached, tissue was rinsed with Krebs three times, 15 minutes each. Aorta rings were stimulated with increasing concentrations of phenylephrine (PHE, 10 −9 to 10 −4 M). In order to investigate endothelial function, vascular tissues were pre-contracted with PHE (10 −6 M) followed by increasing concentrations of acetylcholine (ACh, 10 −9 to 10 −4 M). Participation of endothelium-dependent NO in vascular relaxation was evaluated in concentration-response curves to ACh obtained in the presence of Nω-nitro-L-arginine methyl ester (L-NAME, 3 × 10 −4 mol/L), added in the last 30-minutes stabilization period. 22, 25 Concentration-contraction curves were constructed, and the maximal response to PHE was recorded. Concentration-effect curves to ACh, in the presence or absence of L -NAME, were expressed as the % relaxation to PHE contraction. Non-linear regression (variable slope) of the obtained concentration-effect curves revealed the maximal response (E max ) and negative logarithm of the concentration that evoked 50% of the maximal response (pEC 50 ), as previously described. 21 
| Data analysis and statistics
The results are expressed as means ± SEM. Comparisons between groups were assessed by two-way analysis of variance (ANOVA) or one-way ANOVA followed by Tukey's test (GraphPad Prism ® 6.0, San Diego, CA,
USA). A probability value P < 0.05 was considered significant.
3 | RESULTS
| Pravastatin prevents hypertensive pregnancy and intrauterine growth restriction
No significant differences were observed in systolic blood pressure on gestational day 14 (133 ± 5 to 148 ± 4 mmHg; Figure 1 ). On gestational days 16 and 19, systolic blood pressure was elevated in the HTN-Preg group (163 ± 2 and 160 ± 2 mmHg, respectively; Figure 1 ) compared to the Norm-Preg group (132 ± 2 and 127 ± 1 mmHg, *P < 0.05, respectively; Figure 1 ). However, pravastatin blunted the increases in systolic blood pressure in HTN-Preg+Prava animals on gestational days 16 and 19 (134 ± 2 and 136 ± 2 mmHg, respectively, # P < 0.05; Figure 1 ).
Decreases in foetal weight were found in the HTNPreg group (1.75 ± 0.02 g, *P < 0.05; Figure 2A ) compared to the Norm-Preg and Preg-Prava groups (2.84 ± 0.13 and 2.58 ± 0.06 g, respectively; Figure 2A ). However, pravastatin reversed foetal growth restriction in the HTN-Preg+Prava group (2.4 ± 0.04 g, # P < 0.05; Figure 2A ). Also, placental weight was reduced in the HTN-Preg group (0.25 ± 0.01 g; Figure 2B ) compared to the Norm-Preg group (0.33 ± 0.01 g, *P < 0.05; Figure 2B ). However, the Preg-Prava and HTN-Preg+ Prava groups showed increases in placental weights (0.45 ± 0.01 and 0.46 ± 0.01 g, respectively, * ,# P < 0.05; Figure 2B ). Number of pups presented no significant differences among groups (13 ± 0.7, 11 ± 1.6, 12 ± 0.9 and 12 ± 0.2 were found in the Norm-Preg, Preg-Prava, HTN-Preg and HTN-Preg+Prava groups, respectively; Figure 2C ).
| Pravastatin increases placental NO
formation and prevents significant increases in oxidative stress in hypertensive pregnant rats
Increases in placental NOx were found in HTN-Preg+Prava animals (23 ± 2 μmol/100 mg tissue) compared to the NormPreg (14 ± 2 μmol/100 mg tissue) and HTN-Preg (15 ± 2 μmol/100 mg tissue) groups (* ,# P < 0.05; Figure 3A) . Placental total NOx in the Preg-Prava group (17 ± 3 μmol/100 mg tissue) was similar to those found in the Norm-Preg and HTN-Preg groups ( Figure 3A) . In addition, placental MDA levels were increased in the HTN-Preg group (28 ± 1 nmol/100 mg tissue) compared to Norm-Preg and Preg-Prava animals (16 ± 1 and 17 ± 2 nmol/100 mg tissue, respectively, * ,# P < 0.05; Figure 3B ). However, the HTNPreg+Prava group presented no significant increases in placental MDA levels (22 ± 1 nmol/100 mg tissue) when compared to the Norm-Preg and Preg-Prava groups ( Figure 3B ).
| Pravastatin prevents angiogenic imbalance induced by hypertension in pregnancy
The sFlt-1/PlGF ratio was increased in the HTN-Preg group (12 ± 2) compared to the Norm-Preg group (5 ± 1, *P < 0.05; Figure 4A ). However, pravastatin restored sFlt-1/ PlGF ratio in the HTN-Preg+Prava group (3 ± 0.3, # P < 0.05; Figure 4A ), since similar sFlt-1/PlGF ratios were found when compared to the Norm-Preg and Preg-Prava groups ( Figure 4A ). Also, plasma levels of sFlt-1 were reduced in the HTN-Preg+Prava group (274 ± 32 pg/mL) compared to the Norm-Preg group (450 ± 45 pg/mL, *P < 0.05; Figure 4B ). Similar plasma levels of sFlt-1 were found in the Norm-Preg and Preg-Prava (355 ± 79 pg/mL) groups when compared to the HTN-Preg group (406 ± 29 pg/ mL; Figure 4B ). Also, plasma levels of PlGF were increased Fig. 4C ). Similar plasma levels of PlGF were found in the Norm-Preg (63 ± 11 pg/mL) and Preg-Prava (52 ± 13 pg/mL) groups compared to the HTN-Preg group ( Figure 4C ).
| Pravastatin prevents impaired endothelium-dependent acetylcholine-induced vasodilation and hyper-reactive response to phenylephrine caused by hypertension in pregnancy
While E max to phenylephrine showed no difference among groups ( Figure 5A and Table 1 ), pEC 50 values were only increased in the HTN-Preg group compared to the other groups. However, pravastatin blunted hyper-reactive response to phenylephrine in the HTN-Preg+Prava group ( # P < 0.05; Figure 5A and Table 1 ). In addition, while maximum acetylcholine-induced vasodilation was only impaired in the HTNPreg group compared to the other groups, pravastatin restored maximum acetylcholine-induced vasodilation in the HTNPreg+Prava group ( # P < 0.05; Figure 5B and Table 1) . However, L -NAME inhibited acetylcholine-induced vasodilation in all groups ( Figure 5C and Table 1 ). Moreover, no significant differences among groups were observed in KCl-induced contraction ( Figure 5D and Table 1 ).
| DISCUSSION
The main findings are as follows: (a) pravastatin blunts increases in systolic blood pressure and foeto-placental growth restriction induced by hypertensive pregnancy. (b) Augmented levels of NO in placenta, increased plasma PlGF with concomitant decreased plasma sFlt-1 and reduced sFlt-1/PlGF ratio were found in hypertensive pregnant rats treated with pravastatin. (c) Pravastatin prevented impaired endothelium-dependent acetylcholine-induced vasodilation and hyper-reactive vasoconstrictor response to Insufficiency of the uteroplacental blood flow, angiogenic imbalance and hypertensive pregnancy may be leading events causing pre-eclampsia and abnormal foetal development. 26 These features of pre-eclampsia have been reproduced in the same rat model 19, 20 used in the present study. In line with previous findings, foeto-placental growth restriction with concomitant elevations in systolic blood pressure, in plasma sFlt-1/PlGF ratio and in oxidative stress was observed here (HTN-Preg group) . Also, we Values represent mean ± SEM. *P < 0.05 vs Norm-Preg; # P < 0.05 vs HTN-Preg F I G U R E 4 Plasma levels of anti-angiogenic (soluble fms-like tyrosine kinase-1: sFlt-1) and angiogenic (placental growth factor: PlGF) factors. sFlt-1/PlGF ratio (A) and plasma levels of antiangiogenic (sFlt-1, (B) and pro-angiogenic (PlGF, (C) factors were evaluated among the four groups: normal pregnancy (Norm-Preg), pregnancy+pravastatin (Preg-Prava), hypertensive pregnancy (HTNPreg) and hypertensive pregnancy+pravastatin (HTN-Preg+Prava). Values represent mean ± SEM. *P < 0.05 vs Norm-Preg; # P < 0.05 vs HTN-Preg found impaired endothelium-mediated vasodilation in response to acetylcholine and hyper-reactivity in the contractile response to phenylephrine in thoracic aorta rings of the HTN-Preg group, as previously reported. 20, 22 In addition, although KCl-induced contraction responses suggest that vascular calcium influx through voltage-gated calcium channels could not be behind hyper-reactive response to phenylephrine observed in the HTN-Preg group, 27 it is possible that phenylephrine had further activated calcium influx through receptor and store-operated calcium channels, 27 and thus, a greater calcium influx could have occurred in HTN-Preg rats. Taken together, our present observations support those changes in vascular function and angiogenic imbalance as important mechanisms that underlie hypertension and reduced foeto-placental development. 25, 28, 29 However, our hypothesis was that pravastatin could prevent these deleterious changes.
Results from the HTN-Preg+Prava group confirm our hypothesis and provide evidence that reduced systolic blood pressure, increased foetal and placental weights and restored vascular function involved endothelial and placental NO formation. Supporting these suggestions, enhancing placental NO was only found in the HTN-Preg+Prava group, thus suggesting that placental effect of pravastatin is particular to the concurrent presence of hypertensive pregnancy. 30 Also, pravastatin restored endothelium-dependent acetylcholine-induced vasodilation in the HTN-Preg+Prava group, which was similar to that found in the Norm-Preg group, and this pravastatin effect counteracted hyper-reactive contractile response to phenylephrine in thoracic aorta rings from HTN-Preg+Prava rats. Furthermore, confirming the NO involvement in pravastatin treatment, our findings showed that pre-incubation with a non-selective NO synthase inhibitor (L -NAME 25 ) eliminated endotheliumdependent acetylcholine-induced relaxation.
The increase in plasma sFlt-1/PlGF ratio found in the HTN-Preg group is consistent with earlier studies reporting angiogenic imbalance in women with pre-eclampsia 30 and in animal models. 25, 32, 33 However, the HTN-Preg+Prava group presented elevations in circulating PlGF with concomitant reductions in circulating sFlt-1 and in sFlt-1/PlGF ratio. We suggest that the increase in placental NO formation observed with pravastatin ameliorated angiogenic balance in the HTNPreg+Prava group. In accordance, previous studies have demonstrated NO-mediated regulation of pro-and antiangiogenic genes, resulting in an enhanced PlGF associated with reduced sFlt-1. 15, 16 Consequently, increases in placental NO caused by pravastatin resulted in adequate blood supply into foeto-maternal interface; thus, NO allowed foeto-placental development because it protected against unappropriated remodelling of the maternal uteroplacental vasculature induced by hypertensive pregnancy and that caused foetoplacental growth restriction. 34, 35 Therefore, we believe that the effects of NO signalling may be due to their general effects on angiogenesis, endothelial cell growth, endothelium-dependent vasodilation, vasculogenesis and placental development. 10, 11, 15, 36 We also evaluated antioxidant effects of pravastatin. While the HTN-Preg group showed elevations in oxidative stress, the HTN-Preg+Prava group presented no significant increases compared to those found in Norm-Preg rats. This is similar to other recent findings with pravastatin in hypertensive pregnancy. 11, 37 Of note, antioxidant effect of pravastatin appears to be hypertension-dependent, since the same pravastatin dosage showed no effects in the PregPrava group compared to the Norm-Preg group. Therefore, our results suggest that pleiotropic effects of pravastatin in hypertensive pregnancy include relieving the oxidative stress.
11
While clinicians have major concern to prescribe pravastatin during hypertension in pregnancy, a previous trial has reported that pravastatin concentrations in the umbilical cord, right after delivery, were below the detection limit. 9 Also, experimental studies were addressed to T A B L E 1 Maximal response (E max ) and negative logarithm of the concentration that evoked 50% of the maximal response (pEC 50 ) were recorded for phenylephrine (PHE)-induced contraction, acetylcholine (ACh)-induced vasodilation, ACh-induced vasodilation in the presence of Nω-nitro-L-arginine methyl ester (L -NAME) and KCl-induced contraction in thoracic aorta rings from four groups: normal pregnancy (NormPreg), pregnancy+pravastatin (Preg-Prava), hypertensive pregnancy (HTN-Preg) and hypertensive pregnancy+pravastatin (HTN-Preg+Prava) compare teratogenic effects of statins, and because pravastatin is a polar hydrophilic compound, the authors found no deleterious effects. 9, 38 In accordance, we found that the Preg-Prava group presented foetal weights similar to those found in the Norm-Preg group. Moreover, placental weights were surprisingly higher in animals treated with pravastatin (the Preg-Prava and HTN-Preg+Prava groups), suggesting that there may be a pravastatin-dependent effect which was probably because pravastatin could facilitate trophoblast cell invasion and spiral artery remodelling, resulting in enhanced placental development, as previously reported. 39 Some limitations should be considered. Firstly, DOCA may directly cause premature rupture of amniotic membranes that result in low birthweight. 40 Secondly, previous clinical findings, from small observational studies, showed less convincing effects of pravastatin regarding foetal development, 9, 12 and therefore, further studies are warranted to confirm the pravastatin effects in pregnancies complicated by intrauterine growth restriction. Thirdly, the tail-cuff method may impose a substantial amount of thermal and restrain stress that influences blood pressure measurements. 41 Lastly, placental labyrinth and inverted yolk sac placenta of rat could be more sensitive to hypertension featuring intrauterine growth restriction than the freefloating villi in human beings. 42 
| CONCLUSION
In conclusion, our results implicate that NO underlies pleiotropic effects associated with pravastatin during experimental pre-eclampsia. It is possible that NO formation stimulated by pravastatin restored sFlt-1/PlGF ratio, reestablished endothelium-dependent acetylcholine-induced vasodilation and counteracted the hyper-reactive vasocontraction response to phenylephrine in hypertensive pregnancy. Taken together, these pravastatin effects prevented increases in systolic blood pressure and intrauterine growth restriction induced by hypertension in pregnancy.
